Abstract
Pancreatic cancer (PC) is a highly lethal malignancy often diagnosed at advanced stages due to its asymptomatic early progression. This study identifies the long non-coding RNA (lncRNA) GAS8-AS1 as a potential "liquid biopsy" biomarker. Analysis of 68 PC patients and 62 healthy controls revealed that plasma GAS8-AS1 levels are significantly lower in PC patients. This downregulation effectively distinguishes early-stage PC from healthy controls and correlates with poor 5-year survival. Furthermore, GAS8-AS1 interacts with miR-1179 in a positive feedback loop to inhibit tumor cell migration and invasion.
Introduction
Pancreatic cancer remains a significant clinical challenge with a five-year survival rate below 5%. Because current diagnostic tools often fail to catch the disease early enough for radical treatment, researchers are searching for reliable molecules circulating in the blood that can signal the presence of a tumor. GAS8-AS1, an lncRNA known to inhibit thyroid carcinoma, was investigated here to determine if it plays a similar defensive role in the pancreas.
Methods
The study cohort included 68 PC patients (stages I-IV) and 62 healthy volunteers. Plasma levels of GAS8-AS1 and miR-1179 were quantified using real-time quantitative PCR (qRT-PCR). Functional roles were assessed in pancreatic cancer cell lines (Capan-2 and HPAF-II) through transient transfection and Transwell migration/invasion assays. Diagnostic performance was evaluated using Receiver Operating Characteristic (ROC) curves, and prognostic value was assessed via 5-year overall survival analysis.
Key Results
Downregulation and Diagnostic Potential
Plasma GAS8-AS1 levels were significantly lower in PC patients compared to healthy controls. Notably, this downregulation was observed even in Stage I and II patients, making it a candidate for early-stage screening. ROC curve analysis demonstrated that GAS8-AS1 levels could distinguish PC patients from controls with an Area Under the Curve (AUC) of 0.87, indicating high diagnostic potential.
Prognostic Value and Tumor Suppression
Low plasma levels of GAS8-AS1 were significantly associated with reduced 5-year overall survival (p = 0.037). In vitro experiments showed that overexpressing GAS8-AS1 or miR-1179 significantly inhibited the migration and invasion of Capan-2 and HPAF-II cells. When both were overexpressed, the inhibitory effect was even more pronounced, roughly halving the normalized cell migration compared to controls.
The GAS8-AS1/miR-1179 Feedback Loop
Interestingly, the study found that GAS8-AS1 and miR-1179 positively regulate each other. Transfecting cells with GAS8-AS1 led to an increase in miR-1179, and vice versa. This positive feedback loop creates a reinforced tumor-suppressive environment that limits the metastatic capabilities of PC cells.
Conclusion
GAS8-AS1 serves as a promising non-invasive biomarker for the early diagnosis and prognosis of pancreatic cancer. Its interaction with miR-1179 highlights a novel regulatory mechanism that could be targeted for future therapeutic strategies to improve patient outcomes.
Summary updated